Home | Welcome to Contract Pharma   
Last Updated Monday, May 25 2015


Financial Report: Allergan

Published May 7, 2014
Related Searches: Pharma
1Q Revenues: $1.6 billion (+13%)

1Q Earnings: $257.9 million (earnings were $14.4 million in 1Q13)

Comments: Specialty pharmaceuticals sales increased 10% to $1.4 billion, with Eye Care Pharmaceutical sales of $730.4 million, up 9%, and Botox/Neuromodulators sales up 10% to $501.8 million. Medical devices sales increased 29% to $259.8 million. Earnings in 1Q13 include $258.6 million from discontinued operations associated with the sale of the obesity intervention business unit. On April 22, Allergan received an unsolicited proposal from Valeant Pharmaceuticals to acquire all outstanding shares of Allergan for approximately $47 billion. The Allergan board is currently reviewing the proposal.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On